DK1673092T3 - Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi - Google Patents

Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi

Info

Publication number: DK1673092T3
Authority: DK; Denmark
Prior art keywords: derivatives; disorders; useful; treatment; heterocyclyl
Prior art date: 2003-10-17

Application number

DK04790649T

Other languages

English (en)

Inventor

Mark Jozef Albert Waer

Piet Andre Maurits M Herdewijn

Jonghe Steven Cesar Alfons De

Arnaud Didier Marie Marchand

Ling-Jie Gao

Original Assignee

4 Aza Ip Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2004-10-18

Publication date

2007-12-17

2003-10-17 Priority claimed from GB0324324A external-priority patent/GB2407089A/en

2004-04-22 Priority claimed from GB0408955A external-priority patent/GB2413324A/en

2004-10-18 Application filed by 4 Aza Ip Nv filed Critical 4 Aza Ip Nv

2007-12-17 Application granted granted Critical

2007-12-17 Publication of DK1673092T3 publication Critical patent/DK1673092T3/da

Links

125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
208000035475 disorder Diseases 0.000 abstract 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
206010027654 Allergic conditions Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
150000001204 N-oxides Chemical class 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
229940125721 immunosuppressive agent Drugs 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)

DK04790649T 2003-10-17 2004-10-18 Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi DK1673092T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0324324A GB2407089A (en)	2003-10-17	2003-10-17	Pteridine derivatives
GB0408955A GB2413324A (en)	2004-04-22	2004-04-22	Pharmaceutically active pteridine derivatives
PCT/EP2004/011836 WO2005039587A1 (en)	2003-10-17	2004-10-18	Heterocycle-substituted pteridine derivatives and their use in therapy

Publications (1)

Publication Number	Publication Date
DK1673092T3 true DK1673092T3 (da)	2007-12-17

Family

ID=34525047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04790649T DK1673092T3 (da)	2003-10-17	2004-10-18	Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi

Country Status (11)

Country	Link
EP (1)	EP1673092B1 (da)
JP (1)	JP2007508355A (da)
AT (1)	ATE369862T1 (da)
AU (1)	AU2004283479A1 (da)
CA (1)	CA2537224A1 (da)
DE (1)	DE602004008312T2 (da)
DK (1)	DK1673092T3 (da)
ES (1)	ES2293354T3 (da)
PL (1)	PL1673092T3 (da)
PT (1)	PT1673092E (da)
WO (1)	WO2005039587A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7276506B2 (en)	1998-12-28	2007-10-02	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
WO2008003149A2 (en) *	2006-07-06	2008-01-10	Gilead Sciences , Inc.	Substituted pteridines for the treatment and prevention of viral infections
US9259426B2 (en)	2006-07-20	2016-02-16	Gilead Sciences, Inc.	4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009079A2 (en)	2006-07-20	2008-01-24	Gilead Sciences, Inc.	Substituted pteridines useful for the treatment and prevention of viral infections
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
CN103204816B (zh) *	2012-01-16	2016-04-27	中国人民解放军军事医学科学院毒物药物研究所	哌嗪基嘧啶类衍生物及其制备方法和用途
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
MA38455B1 (fr) *	2013-04-05	2018-05-31	Polichem Sa	Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es)	2014-03-26	2020-04-21	Astex Therapeutics Ltd	Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
JP6752715B2 (ja)	2014-03-26	2020-09-09	アステックス、セラピューティックス、リミテッドＡｓｔｅｘＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	組合せ
TWI719960B (zh)	2015-02-10	2021-03-01	英商阿斯迪克治療公司	新穎組成物
WO2016141092A1 (en)	2015-03-04	2016-09-09	Gilead Sciences, Inc.	Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (da)	2015-09-23	2020-08-24	Janssen Pharmaceutica Nv	Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en)	2015-09-23	2021-03-11	Janssen Pharmaceutica Nv	Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
BR112019001398A2 (pt)	2016-07-29	2019-05-07	Janssen Pharmaceutica Nv	métodos para tratamento de câncer de próstata
EP3507288B1 (en)	2016-09-02	2020-08-26	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh)	2016-09-02	2022-09-13	吉利德科学公司	toll样受体调节剂化合物
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法
TW202208355A (zh)	2020-05-04	2022-03-01	美商安進公司	作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
PE20230609A1 (es)	2020-05-04	2023-04-13	Amgen Inc	Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
CN115485276B (zh) *	2020-05-15	2024-05-31	南京正大天晴制药有限公司	氘代akt激酶抑制剂
CN118121892B (zh) *	2023-06-29	2026-04-17	烟台大学	用于含铬胶原蛋白溶液的除铬降氨剂所用材料

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2940972A (en) *	1957-06-27	1960-06-14	Thomae Gmbh Dr K	Tri-and tetra-substituted pteridine derivatives
DE3445298A1 (de) *	1984-12-12	1986-06-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3833393A1 (de) *	1988-10-01	1990-04-05	Thomae Gmbh Dr K	Verwendung von pteridinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel
HU214331B (hu) *	1992-06-17	1998-03-02	Gyógyszerkutató Intézet Kft.	Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2229803T3 (es) *	1998-12-28	2005-04-16	4 Aza Bioscience Nv	Efectos inmunosupresivos de derivados de pteridina.
US6946465B2 (en) *	1999-02-02	2005-09-20	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
DE19944767A1 (de) *	1999-09-17	2001-03-29	Vasopharm Biotech Gmbh & Co Kg	N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SE0003828D0 (sv) *	2000-10-20	2000-10-20	Astrazeneca Ab	Novel compounds

2004
- 2004-10-18 CA CA002537224A patent/CA2537224A1/en not_active Abandoned
- 2004-10-18 WO PCT/EP2004/011836 patent/WO2005039587A1/en not_active Ceased
- 2004-10-18 ES ES04790649T patent/ES2293354T3/es not_active Expired - Lifetime
- 2004-10-18 PT PT04790649T patent/PT1673092E/pt unknown
- 2004-10-18 JP JP2006534724A patent/JP2007508355A/ja not_active Withdrawn
- 2004-10-18 DK DK04790649T patent/DK1673092T3/da active
- 2004-10-18 DE DE602004008312T patent/DE602004008312T2/de not_active Expired - Fee Related
- 2004-10-18 EP EP04790649A patent/EP1673092B1/en not_active Expired - Lifetime
- 2004-10-18 AU AU2004283479A patent/AU2004283479A1/en not_active Abandoned
- 2004-10-18 AT AT04790649T patent/ATE369862T1/de not_active IP Right Cessation
- 2004-10-18 PL PL04790649T patent/PL1673092T3/pl unknown

Also Published As

Publication number	Publication date
PL1673092T3 (pl)	2008-01-31
PT1673092E (pt)	2007-11-23
JP2007508355A (ja)	2007-04-05
EP1673092B1 (en)	2007-08-15
AU2004283479A1 (en)	2005-05-06
ATE369862T1 (de)	2007-09-15
ES2293354T3 (es)	2008-03-16
DE602004008312D1 (de)	2007-09-27
CA2537224A1 (en)	2005-05-06
DE602004008312T2 (de)	2008-04-17
WO2005039587A1 (en)	2005-05-06
EP1673092A1 (en)	2006-06-28

Publication	Publication Date	Title
DK1673092T3 (da)	2007-12-17	Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
IL185289A0 (en)	2008-02-09	Substituted pyrido (2,3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders
CY1107264T1 (el)	2012-11-21	Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
WO2006069805A3 (en)	2007-01-25	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2009003669A3 (en)	2009-03-19	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
DK1663244T3 (da)	2007-12-03	Pteridin-derivater til behandling af TNF-alpha-beslægtede sygdomme
JOP20230277A1 (ar)	2023-11-02	مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
BR0316256A (pt)	2005-10-04	Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
TW200738660A (en)	2007-10-16	Piperidinyl derivatives as modulators of chemokine receptor activity
MXPA03006863A (es)	2003-11-13	Derivados de oxazolilpirazol com inhibidores de cinasa.
ATE407928T1 (de)	2008-09-15	Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
CY1108932T1 (el)	2014-07-02	Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE369355T1 (de)	2007-08-15	Pyrimidinamid derivate und deren verwendung
EA202190323A1 (ru)	2021-05-28	ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
MX2023010711A (es)	2023-11-10	Fenalquilaminas y métodos de preparación y uso de las mismas.
TW200505448A (en)	2005-02-16	5-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents
CA3242449A1 (en)	2023-06-29	Use of aminopyrazole compounds
TW200503693A (en)	2005-02-01	4-, 6- or 7-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents
GEAP202416375A (en)	2024-01-25	Pro drugs of pde10 compounds
BRPI0516373A (pt)	2008-09-02	derivados de pirido(3,2-d)pirimidinas e uso dos mesmos
DE602004010186D1 (de)	2007-12-27	Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
MX2024014811A (es)	2025-01-09	Composiciones de menaquinol pegilado y metodos de tratamiento
JOP20240259A1 (ar)	2024-11-14	مناهضات at2r واستخدامها